The story of Viagra presents a challenging picture for those considering investment. While the initial launch generated massive gains, the lapse of its patent opened the door to generic competitors, dramatically eroding revenue. This presents a specific risk for firms depending on related blockbuster offerings, suggesting that a blind participation

The legacy of Viagra, and its creator copyright, presents a intriguing case study for investors. Initially a blockbuster drug, producing billions in sales , its intellectual property lapse created a flood of lower-priced alternatives , significantly eroding its dominance. While some pharmaceutical companies may seek to capitalize on male sexual dys